Noticing Neffy – A ‘Transformative Treatment’ For Type 1 Allergies

Richard Lowenthal, co-founder, and CEO of ARS Pharma, highlights the crucial unmet need for needle-free injections. Challenging issues posed by current epinephrine injectors, In Vivo questions the current and future progression of Neffy.

Episode metadata supplied by the publisher feed · Published Oct 8, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

Noticing Neffy – A ‘Transformative Treatment’ For Type 1 Allergies

0:00 31:59

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Citeline Podcasts?

This episode is 31 minutes long.

When was this Citeline Podcasts episode published?

This episode was published on October 8, 2024.

Can I download this Citeline Podcasts episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!